Clinical trials
PET/CT clinical trials
Below are recruiting pet/ct clinical trials, each written for real people, not researchers. We’re tracking 362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05891769RecruitingPhase 2/Phase 3
Compare two scans to find a suspected parathyroid overgrowth
This study compares a Sestamibi scan (with a special camera) versus a Fluorocholine scan (with PET/CT) to see which one better finds a suspected parathyroid adenoma. If your tests suggest a parathyroid problem but the first Sestamibi scan is negative or unclear, this trial may help answer the next best scan choice.
Stanford, CaliforniaAges 18 years+ - NCT05892393RecruitingPhase 1
Scan test to find CD46-positive multiple myeloma lesions
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
San Francisco, CaliforniaAges 18 years+ - NCT05940259Recruiting
68Ga PET/CT scan for prostate cancer imaging
This trial looks at a specific PET/CT scan using a tracer called 68Ga to create detailed images of prostate cancer. It may help doctors see where cancer is in the body more clearly.
Beijing, Beijing MunicipalityAges 18–75 - NCT05957250Recruiting
PET scan study to better image pancreatic and bile duct cancer
This study uses a special PET scan drug (Ga-FAPI-46) to create clearer pictures of pancreatic and bile duct cancers. It may help doctors decide on the best next steps—especially before surgery—by checking tumor size and looking for spread.
Amsterdam, North HollandAges 18 years+ - NCT06056362RecruitingPhase 1/Phase 2
Comparing new PET/CT tracers for neuroendocrine tumors
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
BeijingAges 18–80 - NCT06059469RecruitingPhase 2
PSMA scan for advanced triple-negative breast cancer
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
BrusselsAges 18 years+ - NCT06072807RecruitingPhase 4
Brain imaging study for ER+ breast cancer with brain tumors
This trial tests a special PET scan called FES to see if it can detect estrogen receptors in brain metastases. It may help doctors better target treatment for people with ER+ breast cancer that has spread to the brain.
New York, New YorkAges 18 years+ - NCT06105411Recruiting
PET scan for fungal infections
This trial tests a new PET scan that uses a special marker to see if you have an invasive fungal infection. It may help doctors better diagnose and treat these infections.
Melbourne, VictoriaAges 18 years+ - NCT06107608Recruiting
Scan for tumors in lung cancer patients on immunotherapy
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
BrusselsAges 18 years+ - NCT06122584RecruitingPhase 3
PSMA PET scan for high-risk prostate cancer before surgery
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
NancyAges 18 years+ - NCT06167629Recruiting
PSMA PET scan study for prostate cancer
This study uses a special type of PET scan called PSMA PET to better understand and track prostate cancer. The scan helps doctors see where the cancer is in the body and if treatment is working.
MilanAges 18 years+ - NCT06189820RecruitingPhase 2
FAP protein as a marker for fibrotic lung disease
This trial is looking at a protein called FAP in the blood of people with fibrotic lung diseases. It aims to understand how this protein might be used as a marker to help doctors better diagnose and track these conditions.
BrusselsAges 18 years+ - NCT06191120Recruiting
FAPI PET scan for aggressive colorectal cancer liver metastases
This trial uses a special PET scan (FAPI) to detect a specific, more aggressive type of colorectal cancer (CMS4) in people who have liver tumors that can be surgically removed. The goal is to see if the scan can help doctors choose the best treatment for you.
Utrecht, UtrechtAges 18 years+ - NCT06199713Recruiting
Melanoma trial tracking treatment response with PET scans and blood tests
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Madison, WisconsinAges 18 years+ - NCT06203574Recruiting
TROP-2 PET/CT Scan for Colorectal Cancer Diagnosis
This study tests a new PET/CT scan that uses a special tracer (TROP-2) to take pictures of solid tumors, like colorectal cancer. The goal is to see if this scan can help doctors find and diagnose cancer more accurately.
ShanghaiAges 18–65 - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT06232122Recruiting
New PET scans to detect ovarian cancer recurrence
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
Taoyuan CityAges 30–80 - NCT06260033RecruitingPhase 2
Radiation Therapy for Oligoprogressive ER+ Breast Cancer
This trial tests whether a precise radiation treatment (SBRT) can target a few growing spots of estrogen receptor-positive breast cancer that has spread to other parts of the body. It also uses a special PET scan (FES PET/CT) to see how well the cancer responds. The goal is to slow down the cancer and delay the need for stronger treatments.
Duarte, CaliforniaAges 18 years+ - NCT06277180Recruiting
PET scan guided surgery for medullary thyroid cancer
This trial uses a special PET scan to help guide surgery for medullary thyroid cancer (MTC). The goal is to see if this scan can make surgery more precise.
BeijingAges 18–75 - NCT06320223Recruiting
PSMA PET scan registry for prostate cancer outcomes
This registry collects information from people with prostate cancer who have had a PSMA PET scan. Researchers want to learn how well this scan predicts outcomes over at least 3 years, which may help improve future care.
EssenAges 18 years+ - NCT06330818Recruiting
Imaging study for Moyamoya disease
This study tests different brain imaging methods (MRI and PET/CT) to better understand blood flow and disease activity in people with Moyamoya disease. The goal is to learn more about the condition and possibly find new ways to see how active the disease is.
Tübingen, Baden-WurttembergAges 18–80 - NCT06335069RecruitingPhase 2
Comparing two PET tracers in ER-positive breast cancer
This trial compares two types of PET scans to see which one better detects ER-positive breast cancer. The results could help doctors choose the best scan for tracking your cancer.
MaastrichtAges 18 years+ - NCT06337084RecruitingPhase 1
Imaging test for solid tumors using MNPR-101-DFO*-89Zr
This study tests whether a new imaging agent, MNPR-101-DFO*-89Zr, can find solid tumors and measure their uPAR levels. It might help doctors better understand your cancer and guide future treatment decisions.
North Melbourne, VictoriaAges 18 years+ - NCT06363435Recruiting
AI study of tumor burden on PSMA PET-CT scans
This trial tests an AI tool that measures tumor burden on PSMA PET-CT scans. If you are having this scan for prostate cancer, it could help doctors get more detailed information from your images.
LundAges 20–120
Hear when a new PET/CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pet/ct?
- Yes. Clin2 currently lists 362 recruiting pet/ct studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pet/ct trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pet/ct trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.